Navigation Links
Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
Date:6/9/2008

and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

This press release includes forward-looking statements regarding the potential timing of the announcement of results of the AZ-004 Phase 3 clinical trial, potential benefits of AZ-004, future development of the Company's product candidates and safety of the Company's products and technologies. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission including the risks under the headings: "Failure or delay in commencing or completing clinical trials for our product candidates could harm our business" and "If our product candidates do not meet safety and efficacy endpoints in clinical trials, they will not receive regulatory approval, and we will
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014 Research and ... the addition of the "Micro Market Monitor: ... to their offering. ... treatment is progressing steadily, which has resulted in ... devices market. The main purpose of these dermatology ...
(Date:12/19/2014)... 2014  Decision Resources Group finds that the laparoscopic ... will increase to a value of over $4.3 ... expansion in the large direct energy device market. In ... adopted due to the advantages they offer and as ... from Decision Resources Group,s coverage of the U.S. laparoscopic ...
(Date:12/19/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year 2015 results on Thursday, January 22, 2015, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
Breaking Medicine Technology:Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3ResMed To Announce Second Quarter 2015 Results 2
... MOUNT PROSPECT, Ill., March 22, 2011 The National Association ... the prescription monitoring programs (PMPs) of North Dakota , ... agreements to participate in the PMP Interconnect ™ system, ... United States to be linked, providing a more effective means ...
... 22, 2011 The U.S. Food and Drug Administration ... Ann Arbor, Mich., and two of its officers, Mark ... Lincoln, vice president of Quality Assurance and Operations, have ... (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) The ...
Cached Medicine Technology:Three States Sign on to Participate in NABP's Interconnected Prescription Monitoring System 2Three States Sign on to Participate in NABP's Interconnected Prescription Monitoring System 3FDA: Michigan Heart-Lung Bypass Machine Manufacturer Enters Into Consent Decree 2FDA: Michigan Heart-Lung Bypass Machine Manufacturer Enters Into Consent Decree 3
(Date:12/20/2014)... December 20, 2014 Angeldress.co.uk, the distinguished ... great for worldwide dress fans. The company has recently ... and information. For the holiday season, Angeldress Blog ... special wedding apparel. , Angeldress.co.uk prides itself in offering ... level of service. All the company’s outfits are very ...
(Date:12/20/2014)... San Francisco, CA (PRWEB) December 20, 2014 ... a Social Innovation company just launched first birthday focused ... the services, “MERRY BIRTHDAY MESSAGE” launched in both US ... , MERRY BIRTHDAY MESSAGE : http://merrybirthday.net/message/ , ... launching for everyone’s birthday around the world. , Features, ...
(Date:12/20/2014)... Recently, AngelWeddingDress.com has introduced its special ... the coming Christmas. In the promotion, all buyers worldwide ... “We have something special for the women who are ... Moreover, our new collections of 2015 dresses have been ... at greatly discounted prices. Visit our website now before ...
(Date:12/20/2014)... Xarelto bleeding lawsuits filed by men and ... other serious side effects will be consolidated in the ... pretrial proceedings, Wright & Schulte LLC reports. The U.S. ... Friday to transfer 21 Xarelto lawsuits and over 30 ... the Louisiana district court for coordination by Judge Eldon ...
(Date:12/20/2014)... Parker & Sons, Inc. a focused and dedicated ... contractor services announces reaching a milestone by providing 40 ... Arizona. Parker and Sons is comprised of a reliable ... customer service the number one priority. The company was ... one service vehicle and has since grown to become ...
Breaking Medicine News(10 mins):Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:AngelWeddingDress Has Introduced Its Special Offer For The Coming Christmas 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 3
... people become less efficient at separating important from less ... Knowing this, clinicians may be able to train people ... information better, according to a report in the May ... Psychological Association. , Remembering what,s most important is ...
... PARK, Calif., May 4 Acclarent, Inc., the pioneer ... the treatment of chronic sinusitis, announced today that the ... 7,500,971, entitled "Devices, Systems and Methods for Treating Disorders ... This patent and Acclarent,s earlier 7,462,175 patent are ...
... Commonsense Steps to Prevent Spreading FluNORRISTOWN, Pa., May 3 ... Pennsylvania,s first laboratory-confirmed case of 2009 A/H1N1 in a ... a confirmed case, it is even more important for ... that can help prevent the spread of the flu," ...
... 2009) Identifying one of the processes that plays a ... one day lead to better vaccines and possibly more effective ... Texas Children,s Hospital in a report that appears in the ... work, Dr. Daniel Lacorazza, assistant professor of pathology at BCM, ...
... Journalistic Achievement Award Winners , ... New York, NY ... ABC News 20/20 are among winners receiving top honors in the ... Plastic Surgery (ASAPS). Selected from over 125 entries, this year,s ...
... of liposuction will be discussed by leading experts at the Annual Meeting ... the Mandalay Bay Hotel & Convention Center May 2-7, 2009. , ... ... will be discussed by leading experts at the Annual Meeting of the ...
Cached Medicine News:Health News:Memory grows less efficient very early in Alzheimer's disease 2Health News:Acclarent, Inc. Granted Key Patent Covering Balloon Sinuplasty(TM) Technologies 2Health News:Governor Rendell Announces Pennsylvania's First Confirmed Case of 2009 A/H1N1 Flu 2Health News:Governor Rendell Announces Pennsylvania's First Confirmed Case of 2009 A/H1N1 Flu 3Health News:Process controlling T cell growth and production identified 2Health News:Aesthetic Society Awards Journalists' Commitment To Patient Education 2Health News:Aesthetic Society Awards Journalists' Commitment To Patient Education 3Health News:Liposuction Turns 20 2Health News:Liposuction Turns 20 3Health News:Liposuction Turns 20 4
Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
... innovative E.coli 0157 latex ... definitive identification of E.coli ... of a proprietary antibody ... of cross-reactions with Escherichia ...
Inquire...
The Onar®Lp test system is an in vitro test for the qualitative diagnosis of legionella in clinical samples....
Medicine Products: